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We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A
total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily
for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All
patients achieved clinically significant responses to ATO. The overall complete response rate and overall response
rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in
patients with refractory SAA.
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No standard therapies are available for patients who
have severe aplastic anemia (SAA) that is refractory
to immunosuppressive therapy and are ineligible for
hematopoietic stem cell transplantation (HSCT). For such
patients, an alternative protocol is urgently needed.
From May 2009 to June 2010, a total of 5 consecutive
adults (age range, 21–43 years) with a diagnosis of SAA,
defined according to standard criteria [1], entered into
this study. All of them failed one or two courses of horse
or rabbit anti-thymocyte globulin/cyclosporine-based
regimens and all of them did not have a suitable donor
for HSCT . Other eligibility criteria included adequate
hepatic functions, adequate renal function, and adequate
cardiac status. The study was approved by the Institu-
tional Review Board.
None of the patients received any immunosuppressive
or cytokine therapy for at least 2 month prior to enroll-
ment. Eligible patients received arsenic trioxide (ATO)
at a dose of 0.15 mg/kg intravenously daily for 5 days
every week for 8 weeks. If necessary, a second course
was performed after an interval of one week. Complete
response (CR) was defined as satisfaction of all three* Correspondence: sunfbj@126.com
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reproduction in any medium, provided the orperipheral blood count criteria: (1) absolute neutrophil
count (ANC) > 1 × 109/L; (2) haemoglobin > 10 g/dL;
(3) platelet count > 100 × 109/L. Partial response (PR)
was defined as transfusion independence associated with
ANC greater than 0.5 × 109/L, haemoglobin greater than
8 g/dL, and platelet count greater than 30 × 109/L.
Transfusion dependence was taken as evidence of no re-
sponse. Relapse was indicated by the requirement for
red blood cells or platelets transfusion after having been
independent from transfusions for at least 3 months.
The clinical characteristics of patients and outcomes
after ATO treatment are summarized in Tables 1 and 2.
The overall response rate at 8 weeks was 100% (5/5)
after the initiation of treatment, including 20% (1/5) CR
and 80% (4/5) PR. The median time to initial response
was 43 days (range, 41– 48 days). Four patients with a
PR received a second course of ATO and continued to
have clinically significant improvements in blood counts.
Two of them eventually met response criteria for CR at
17 weeks after the initiation of treatment. So the overall
CR rate and overall response rate at 17 weeks were 60%
(3/5) and 100%(5/5), respectively. Serial bone marrow bi-
opsies showed hematopoietic recovery accompanied by a
decrease in adipocyte number in patients after getting a
response (Figure 1). Actuarial survival was 100% at 1
year and 80% at 2 years. No patient showed evidence of
clonal evolution or cytogenetic abnormalities at the last
follow-up visit.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






























1 21/M 35 2 9.8 Primary refractory# 41 56 CR CR and well
34 months
2 37/F 71 1 11 Relapsed refractory† 43 102 PR PR and well
28 months
3 43/M 38 2 13.4 Primary refractory 42 87 CR CR and well
25 months
4 35/F 41 2 9.2 Primary refractory 46 69 CR Relapsed and
transfusion
dependent
5 29/M 63 2 10.3 Primary refractory 48 108 PR PR and well
20 months
M, male; F, female; IST, Intensive immunosuppressive therapy; ATO, arsenic trioxide; CR, complete response; PR, partial response.
*IST regimens included horse antithymocyte globulin (ATG), rabbit ATG, cyclophosphamide, and fludarabine.
#Primary refractory disease was defined as no prior adequate response to IST.
†Relapsed refractory disease was defined as a prior adequate response to at least one regimen of IST.
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reactions (rash, itching, erythema), 2 of 5 with gastro-
intestinal reactions (vomiting, nausea, diarrhea), 1 of 5
with liver dysfunction, and 2 of 5 with facial edema. All
the side effects were modest and responded to symp-
tomatic treatment. No patient discontinued therapy be-
cause of ATO-related toxicities.
Studies suggest that bone marrow adipocytes are pre-
dominantly negative regulators of the bone marrow
microenvironment [2]. Bone marrow adipocytes are less
supportive of hematopoiesis than those of other cell
types derived from mesenchymal progenitors such as
bone marrow myofibroblasts or osteoblasts [3,4]. In
addition, it has been shown that ablation of the bone
marrow adipocyte compartment can induce osteogen-
esis [2], which promotes a more supportive environ-
ment for hematopoietic reconstitution [2,5]. This is in
accordance with the data that surgical removal of the
adipocyte-rich marrow induces hematopoietic infiltra-
tion and new osteoid and trabecular bone formation
in rabbit tibias [6]. Considering that adipocytes andTable 2 Patients’ characteristics before and after ATO treatme
Patient
No.







1 1.8 Transfusion independence 9
2 1.9 Transfusion independence 11
3 2.3 Transfusion independence 14
4 2.6 Transfusion independence 9
5 1.9 Transfusion independence 5
RBC, red blood cells; ATO, arsenic trioxide; ANC, absolute neutrophil count.osteoblasts originate from the common precursor, mes-
enchymal stem cells (MSCs), within the bone marrow,
where both display an inverse or reciprocal relationship
[7], and that ATO could regulate the adipogenic and
osteogenic differentiation of MSCs by significantly inhi-
biting adipogenic differentiation and enhancing MSCs
osteogenic differentiation [8], ATO might be used to
improve hematopoiesis in SAA patients.
Recently, we administered arsenic trioxide (ATO) plus
cyclosporine in patients with SAA. The overall complete
response rate and overall response rate at 17 weeks after
the initiation of treatment were 80% (8/10) and 100%
(10/10), respectively [9]. This observation prompted us
to investigate whether ATO has activity in patients with
SAA who have persistent, severe cytopenia after one
or more cycles of immunosuppressive therapy. In
this study, all patients achieved clinically significant
responses to ATO. Therefore ATO could represent a
reasonable salvage treatment in those patients with re-
fractory SAA. The current study is being expanded to
gain more data on this novel approach.nt





















115 5.1 11.4 0.2 2.0
73 5.3 8.6 0.1 0.8
138 4.9 11.2 0.3 1.9
107 6.1 12.3 0.2 2.2
67 5.7 8.8 0.2 0.9
Figure 1 Hematopoietic recovery in five patients with refractory aplastic anemia after arsenic trioxide therapy. Bone marrow biopsy
specimens were obtained from the five patients. Specimens from pre- and post-treatment (at 8 weeks) were shown. (Hematoxylin and eosin
stain; Original magnification: × 100)
Li et al. Journal of Hematology & Oncology 2012, 5:61 Page 3 of 4
http://www.jhoonline.org/content/5/1/61
Li et al. Journal of Hematology & Oncology 2012, 5:61 Page 4 of 4
http://www.jhoonline.org/content/5/1/61Competing interests
The authors declare that they have no competing interests.
Author contributions
Study concept and design: BF and NL; Acquisition of data: NL, YS, JZ and BF.
Analysis and interpretation of data: BF, NL and YS. Drafting of the
manuscript: NL, YS, JZ and BF. All authors have read and approved the final
manuscript.
Acknowledgements
The authors would like to thank all patients for their cooperation. This study
was supported by grants from the National Natural Science Foundation of
China (No. 30900637) and the National Natural Science Foundation of China
(No. 81070398).
Received: 3 October 2012 Accepted: 4 October 2012
Published: 9 October 2012
References
1. Rosenfeld S, Follmann D, Nunez O, Young NS: Antithymocyte globulin and
cyclosporine for severe aplastic anemia: association between
hematologic response and long-term outcome. JAMA 2003,
289:1130–1135.
2. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ: Bone-
marrow adipocytes as negative regulators of the haematopoietic
microenvironment. Nature 2009, 460:259–263.
3. Corre J, Barreau C, Cousin B, Chavoin JP, Caton D, Fournial G, Penicaud L,
Casteilla L, Laharrague P: Human subcutaneous adipose cells support
complete differentiation but not self-renewal of hematopoietic
progenitors. J Cell Physiol 2006, 208:282–288.
4. Nishikawa M, Ozawa K, Tojo A, Yoshikubo T, Okano A, Tani K, Ikebuchi K,
Nakauchi H, Asano S: Changes in hematopoiesis-supporting ability of
C3H10T1/2 mouse embryo fibroblasts during differentiation. Blood 1993,
81:1184–1192.
5. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin
RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden
DT: Osteoblastic cells regulate the haematopoietic stem cell niche.
Nature 2003, 425:841–846.
6. Tavassoli M, Maniatis A, Crosby WH: Induction of sustained hemopoiesis in
fatty marrow. Blood 1974, 43:33–38.
7. Nuttall ME, Gimble JM: Controlling the balance between
osteoblastogenesis and adipogenesis and the consequent therapeutic
implications. Curr Opin Pharmacol 2004, 4:290–294.
8. Cheng H, Qiu L, Zhang H, Cheng M, Li W, Zhao X, Liu K, Lei L, Ma J: Arsenic
trioxide promotes senescence and regulates the balance of adipogenic
and osteogenic differentiation in human mesenchymal stem cells. Acta
Biochim Biophys Sin (Shanghai) 2011, 43:204–209.
9. Song Y, Li N, Liu Y, Fang B: Improved outcome of adults with aplastic
anemia treated with arsenic trioxide plus cyclosporine. Br J Haematol.
In press.
doi:10.1186/1756-8722-5-61
Cite this article as: Li et al.: Arsenic trioxide improves hematopoiesis in
refractory severe aplastic anemia. Journal of Hematology & Oncology 2012
5:61.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
